Polchi P, Lucarelli G, Galimberti M, Giardini C, Baronciani D, Angelucci E, Sparaventi G, Capponi D, Talevi N, Debiagi M
Divisione di Ematologia e Centro Trapianto Midollo Osseo di Muraglia, Azienda Autonoma Ospedale San Salvatore di Pesaro, Italy.
Bone Marrow Transplant. 1995 Oct;16(4):529-35.
Use of the mother as mismatched marrow donor was assessed in 19 children with advanced leukemia. Patients were homogeneous for HLA incompatibility, age, donor, and conditioning regimen, and stage of disease. All received busulfan and cytoxan, combined with unmodified donor marrow, ALG given before and after transplant, and short MTX and cyclosporine as GVHD prophylaxis. Survival, LFS, and relapse respectively were 26, 26, and 33%. Incidence of overall and severe acute GVHD was 58 and 32%, respectively. Four patients had failure of engraftment, and two of these are alive with autologous reconstitution in complete remission. Probability of rejection was 21%. Results of haploidentical transplants were compared with those of children with advanced leukemia treated at the same institution, who received marrow from HLA-identical siblings. The probability of long-term leukemia-free survival was similar in the two groups. We thus propose using the mother as an alternative marrow donor in children with advanced leukemia.
在19名晚期白血病患儿中评估了使用母亲作为不匹配骨髓供者的情况。患者在HLA不相容性、年龄、供者、预处理方案及疾病分期方面具有同质性。所有患者均接受白消安和环磷酰胺,联合未处理的供者骨髓,移植前后给予抗淋巴细胞球蛋白,以及短期甲氨蝶呤和环孢素预防移植物抗宿主病(GVHD)。生存率、无白血病生存率和复发率分别为26%、26%和33%。总体急性GVHD和严重急性GVHD的发生率分别为58%和32%。4例患者植入失败,其中2例存活,自体造血重建且处于完全缓解状态。排斥概率为21%。将单倍体移植的结果与在同一机构接受来自HLA相同同胞骨髓治疗的晚期白血病患儿的结果进行了比较。两组长期无白血病生存的概率相似。因此,我们建议在晚期白血病患儿中使用母亲作为替代骨髓供者。